Parp-Inhibitors have long been on AnCan’s radar since our dear departed Boardie, Dr. Bill Burhans, found himself with olaparib in his lab in 2015 and convinced his tumor board to prescribe it along with abiraterone for his BRCA2 mutation.
Question is …
What’s a PARP-Inhibitor, and what does it do?
Who benefits from a PARP?
Do PARP-I’s work for everybody?
How can a PARP-I be used for prostate cancer?
AnCan brings you two experts to discuss. Dr. Pamela Munster of the UCSF BRCA Research Institute with her unique peer perspective, and Dr. Neal Shore who just released the TALAPRO-2 Study using a PARP with Xtandi.
Watch here:
Special thanks to Bayer, Pfizer, Myovant Sciences, Foundation Medicine, Myriad Genetics, Janssen – Johnson & Johnson, Telix, and Blue Earth Diagnostics for sponsoring this webinar.
For information on our peer-led video chat PROSTATE CANCER VIRTUAL SUPPORT GROUPS, click here.
To SIGN UP for any of our Virtual Support groups, visit our Contact Us page.